We are live on !
Find out more
Cliff Asness AQR Capital Management
AUM
$287B
Turnover
8.35%
1-Year Est. Return
42.33%
Cliff Asness is a co-founder of AQR Capital Management, a leading quantitative investment firm spanning equities, alternatives, and factor strategies. He is known for academic-informed research on value, momentum, and other systematic premia, as well as candid market commentary. Asness’s work bridges academic finance and large-scale institutional portfolio management.
This Fund
S&P 500
This Quarter Est. Return
+22.95%
1 Year Est. Return
+42.33%
3 Year Est. Return
+119.89%
5 Year Est. Return
+147.33%
10 Year Est. Return
+543.74%
AUM
$287B
AUM Growth
+$68.5B
(+31%)
Cap. Flow
+$37.5B
Cap. Flow % of AUM
Cap. Flow %
13.08%
Top 10 Holdings %
Top 10 Hldgs %
12.15%
Holding
3,986
New
247
Increased
2,455
Reduced
1,098
Closed
86
Avg Time Held
4.1
years
Top 10 Avg Time Held
3.3
years
Top 20 Avg Time Held
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.17B |
| 2 |
Apple
AAPL
|
+$849M |
| 3 |
Chevron
CVX
|
+$746M |
| 4 |
Synopsys
SNPS
|
+$643M |
| 5 |
Wells Fargo
WFC
|
+$633M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$517M |
| 2 |
Booking.com
BKNG
|
+$488M |
| 3 |
Walmart Inc
WMT
|
+$414M |
| 4 |
Sandisk
SNDK
|
+$355M |
| 5 |
Cigna
CI
|
+$325M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.5% |
| 2 | Financials | 14.38% |
| 3 | Industrials | 14.2% |
| 4 | Consumer Discretionary | 10.53% |
| 5 | Healthcare | 10.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3151
Viant Technology
DSP
$269M
| $776K | ﹤0.01% |
61,292
+12,026
| +24% | +$136K |
2024 Q2
8 quarters
|
|
3152
Surgery Partners
SGRY
$2.99B
| $775K | ﹤0.01% |
46,155
+34,202
| +286% | +$480K |
2026 Q1
1 quarter
|
|
3153
iShares International Small Cap Equity Factor ETF
ISCF
$696M
| $775K | ﹤0.01% |
17,891
+7,891
| +79% | +$349K |
2026 Q1
1 quarter
|
|
3154
Lucid Diagnostics
LUCD
$77.6M
| $774K | ﹤0.01% |
723,200
+488,431
| +208% | +$526K |
2025 Q3
3 quarters
|
|
3155
NewAmsterdam Pharma
NAMS
$2.37B
| $769K | ﹤0.01% |
22,691
+12,307
| +119% | +$406K |
2025 Q3
3 quarters
|
|
3156
Caledonia Mining Corp
CMCL
$386M
| $768K | ﹤0.01% |
40,191
+10,551
| +36% | +$239K |
2025 Q2
4 quarters
|
|
3157
Citizens Community Bancorp
CZWI
$226M
| $767K | ﹤0.01% |
32,783
+9,964
| +44% | +$209K |
2025 Q3
3 quarters
|
|
3158
Vanguard Short Duration Bond ETF
VSDB
$999M
| $767K | ﹤0.01% |
10,044
| – | – |
2025 Q4
2 quarters
|
|
3159
T. Rowe Price Small-Mid Cap ETF
TMSL
$3.15B
| $765K | ﹤0.01% |
17,437
+10,387
| +147% | +$424K |
2025 Q3
3 quarters
|
|
3160
PIMCO RAFI Dynamic Multi-Factor US Equity ETF
MFUS
$304M
| $764K | ﹤0.01% |
11,374
+1,814
| +19% | +$115K |
2025 Q4
2 quarters
|
|
3161
Ascent Industries
ACNT
$123M
| $764K | ﹤0.01% |
50,816
+22,360
| +79% | +$312K |
2025 Q3
3 quarters
|
|
3162
FT Vest US Equity Buffer ETF April
FAPR
$1.33B
| $760K | ﹤0.01% |
16,266
-1,098
| -6% | -$50.5K |
2025 Q3
3 quarters
|
|
3163
Precision Drilling
PDS
$1.32B
| $759K | ﹤0.01% |
+9,888
| New | +$903K |
2026 Q2
0 quarters
|
|
3164
Schwab International Dividend Equity ETF
SCHY
$2.69B
| $758K | ﹤0.01% |
+23,900
| New | +$771K |
2026 Q2
0 quarters
|
|
3165
Vanguard S&P Mid-Cap 400 Growth ETF
IVOG
$1.64B
| $757K | ﹤0.01% |
5,177
+473
| +10% | +$65.3K |
2025 Q4
2 quarters
|
|
3166
CVR Energy
CVI
$5.84B
| $756K | ﹤0.01% |
27,465
-91,219
| -77% | -$2.9M |
2025 Q1
5 quarters
|
|
3167
Core Laboratories
CLB
$483M
| $755K | ﹤0.01% |
64,809
+12,884
| +25% | +$184K |
2025 Q3
3 quarters
|
|
3168
Invesco BulletShares 2030 Corporate Bond ETF
BSCU
$2.81B
| $754K | ﹤0.01% |
45,295
+3,100
| +7% | +$51.8K |
2024 Q3
7 quarters
|
|
3169
GPGI Inc
GPGI
$3.15B
| $752K | ﹤0.01% |
47,463
-56,119
| -54% | -$803K |
2024 Q4
6 quarters
|
|
3170
Bentley Systems
BSY
$12.2B
| $751K | ﹤0.01% |
25,203
+7,406
| +42% | +$241K |
2025 Q2
4 quarters
|
|
3171
E.W. Scripps
SSP
$244M
| $750K | ﹤0.01% |
270,835
+86,863
| +47% | +$329K |
2024 Q1
9 quarters
|
|
3172
Edgewise Therapeutics
EWTX
$4.15B
| $750K | ﹤0.01% |
18,456
+9,917
| +116% | +$342K |
2025 Q4
2 quarters
|
|
3173
Health Catalyst
HCAT
$126M
| $749K | ﹤0.01% |
376,586
-166,658
| -31% | -$241K |
2024 Q2
8 quarters
|
|
3174
iShares Morningstar Growth ETF
ILCG
$2.97B
| $748K | ﹤0.01% |
6,395
| – | – |
2026 Q1
1 quarter
|
|
3175
ArriVent BioPharma
AVBP
$720M
| $748K | ﹤0.01% |
21,517
+5,594
| +35% | +$165K |
2025 Q2
4 quarters
|
|
Similar funds
Cliff Asness's Q2 2026 Portfolio in Review
As of Q2 2026, Cliff Asness held 3,986 positions worth $287B, up 31% from $218B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Cliff Asness deployed $37.5B of net new capital in Q2 2026, opening 247 new positions and adding to 2,455 existing holdings. Its largest new stake was FedEx Freight: 1,024,555 shares worth $155M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 22% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Micron Technology, an estimated $517M trimmed.
- Cliff Asness's largest Q2 2026 buy was FedEx Freight: 1,024,555 shares worth $155M.
- Cliff Asness added most to NVIDIA in Q2 2026, an estimated $1.17B increase.
- Cliff Asness's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $517M.
- Cliff Asness fully exited Masimo in Q2 2026, selling an estimated $147M.
- Cliff Asness's ten largest holdings make up 12% of its $287B portfolio in Q2 2026.
- Cliff Asness opened 247 new positions and closed 86 in Q2 2026.
- Cliff Asness's portfolio value rose 31% quarter-over-quarter to $287B.
Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.